AuT-1
Exudative eye diseases (e.g., wet AMD, diabetic macular edema)
Pre-clinicalActive
Key Facts
Indication
Exudative eye diseases (e.g., wet AMD, diabetic macular edema)
Phase
Pre-clinical
Status
Active
Company
About Authera
Authera is a science-driven biotech founded in 2022, building on decades of foundational research in FcRn biology from its academic founders. The company operates a cutting-edge technology platform that integrates biochemical, cellular, and in vivo models to de-risk the development of novel biologics with fine-tuned FcRn interactions. With a lead program in pre-clinical development for severe eye diseases and recent non-dilutive grant funding, Authera is positioned to advance its pipeline while seeking strategic partnerships to explore the broad therapeutic utility of its platform.
View full company profile